



(19) Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number: 0 277 676 B1

(12)

## EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: 04.03.92 (51) Int. Cl.<sup>5</sup>: C07J 41/00, C07J 1/00,  
C07J 15/00, C07J 21/00,  
(21) Application number: 88200071.4 C07J 71/00, A61K 31/565,  
A61K 31/585  
(22) Date of filing: 18.01.88

The file contains technical information submitted  
after the application was filed and not included in  
this specification

### (54) New II-aryl steroid derivatives.

- (30) Priority: 23.01.87 NL 8700157  
(43) Date of publication of application:  
10.08.88 Bulletin 88/32  
(45) Publication of the grant of the patent:  
04.03.92 Bulletin 92/10  
(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI NL SE  
(56) References cited:  
EP-A- 0 057 115  
EP-A- 0 129 499

STEROIDS, vol. 44, no. 6, December 1984,  
pages 519-530, Holden Day, San Francisco,  
US; E. OTTOW et al.: "Synthesis of ENT-  
17-(prop-1-ynyl-17beta-hydroxy-11beta-(4-(N,-  
N-dimethylamino)-phenyl)-4,9-estradien-3-o-  
ne, the antipode of RU - 38 486"

- (73) Proprietor: AKZO N.V.  
Velperweg 76  
NL-6824 BM Arnhem(NL)  
(72) Inventor: Loozen, Hubert Jan Jozef  
Meerhoek 602  
NL-5403 AC Uden(NL)  
(74) Representative: Hermans, Franciscus G.M. et  
al  
Patent Department AKZO N.V. Pharma Di-  
vision P.O. Box 20  
NL-5340 BH Oss(NL)

EP 0 277 676 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**Description**


The invention relates to new 11-aryl steroid derivatives, to methods for preparing said compounds and also to pharmaceutical products which contain said derivatives as active constituent.

5 Antiprogestins are substances which have affinity for the progesterone receptors, such substances not having, or having to a considerably reduced degree, the action of progesterone and/or which inhibit progesterone biosynthesis. Progesterone is involved, inter alia, in the implantation of a fertilized egg cell in the wall of the uterus. It will be possible to prevent implantation by occupying receptor sites in the cells of the uterus and/or to inhibit progesterone biosynthesis with antiprogestins, as a result of which the 10 pregnancy can be terminated at a very early stage. Antiprogestins are known from the European Patent Application 0,057,115 and the German Offenlegungsschrift DE 3,413,036.

It has been found however that, in addition to the desired antiprogestinic activity, such antiprogestins also have an antiglucocorticoid activity which is not desirable if said substances are used as a pregnancy-terminating agent.

15 A new group of compounds has now been found which have a strong antiprogestinic and a weak or non-existent antiglucocorticoid activity.


The invention therefore relates to steroids having the following formula:



30 wherein

R<sub>1</sub> is a homocyclic or heterocyclic aryl group having one of the following substituents: an optionally saturated or unsaturated, branched or unbranched hydrocarbon radical containing 1-10 carbon atoms, the hydrocarbon radical being optionally provided with a hydroxyimino, oxo and/or hydroxyl group, or a

35



group, where X and Y are each separately H or a hydrocarbon (1-4 C) radical or are together a hydrocarbon (2-6 C) radical;

R<sub>2</sub> is an alkyl group containing 1-4 carbon atoms;

45 R<sub>3</sub> is H, OH, a saturated or unsaturated hydrocarbon radical containing 1-8 carbon atoms, optionally provided with one or more hydroxyl, azido, nitrile, oxo and/or halogen groups, or is a (1-18 C) acyloxy or (2-8 C) alkoxyalkyl or (1-18 C) acyl or (1-12 C) alkoxy group;

R<sub>4</sub> is an H, OH, a saturated or unsaturated hydrocarbon radical containing 1-8 carbon atoms, optionally provided with one or more hydroxyl, azido, nitrile, oxo and/or halogen groups, or is a (1-18 C) acyloxy or (2-8 C) alkoxyalkyl or (1-18 C) acyl or (1-12 C) alkoxy group; or R<sub>3</sub> and R<sub>4</sub> together form a ring system or an alkylidene group having 1-6 carbon atoms and the dotted line represents an optional bond between the carbon atoms 16 and 17 of the steroid skeleton, with the proviso that R<sub>3</sub> or R<sub>4</sub> is absent if said bond between said carbon atoms 16 and 17 is present.

Other 14-β steroids are known from Steroids, 44, 519 (1984). However, in contrast to the compounds of this invention, the compounds disclosed in said reference have their 13-methyl group in the α position. One of the compounds of this Steroids reference was tested and reported not to have abortive properties.

The aryl group in R<sub>1</sub> may be derived from, for example, benzene, biphenyl, naphthalene, anthracene, phenanthrene, or a heterocyclic aromatic compound such as pyridine, thiazole, thiophene, pyrrole, furan,


benzothiophene, benzofuran, pyrimidine, pyrazine, purine and imidazole.

- If the aryl group is not heterocyclic, preference is given to the phenyl group. If the aryl group is heterocyclic, preference is given to nitrogen- and/or sulphur-containing heterocyclic groups, such as those derived from pyridine, pyrrole, thiazole, thiophene, benzothiophene, pyrimidine, pyrazine, purine and imidazole. Phenyl is the most preferred. In the case of a phenyl group, the substituent is preferably located in the meta or para position.

- The substituent on the aryl group may be a branched or unbranched, saturated or unsaturated hydrocarbon radical containing 1-10 carbon atoms, optionally provided with a hydroxyimino, hydroxyl and/or oxo group, such as methyl, ethyl, propyl, isopropyl, hexyl, 3-methylheptyl, ethenyl, ethynyl, propenyl, 10 acetyl, propionyl, hexanoyl, 1-hydroxyiminoethyl, 1-hydroxyiminopropyl, butyryl, formyl, 2-oxobutyl, hydroxymethyl, 3-hydroxyhexyl, hydroxyethyl and 8-hydroxyoctyl. Preferably, the hydrocarbon radical substituent on the aryl group is an acyl group having 1-4 carbon atoms.


The substituent on the aryl group may furthermore be a group with the formula:

15



- If X and Y each separately are hydrocarbon radicals (1-4 C), such a radical may be methyl, ethyl, vinyl, ethynyl, propyl, 2-propenyl, allenyl, 1-propynyl, butyl or branched analogues thereof. If X and Y together form a hydrocarbon radical (2-6 C), said hydrocarbon group may be saturated or unsaturated; preferably, such hydrocarbon radical contains 4 or 5 carbon atoms. If X and Y do not together form a hydrocarbon radical preferably, X and Y are each separately H or a saturated alkyl group containing 1-3 carbon atoms .
- 25 The most preferred substituents on the aryl group are an acyl group having 1-4 carbon atoms or a group

30



- X and Y separately being H or a saturated alkyl group having 1-3 carbon atoms. R<sub>2</sub> is preferably ethyl or methyl and still more preferably methyl. The (1-8 C) hydrocarbon radical R<sub>3</sub> and R<sub>4</sub> may be, inter alia, 35 methyl, ethyl, vinyl, ethynyl, propyl, 2-propenyl, allenyl, 1-propynyl, butyl, octyl or an analogue provided with one or more hydroxyl, azido, nitrile, oxo and/or halogen groups, such as 3-hydroxyl-1-propynyl, 3-hydroxy-1-propenyl, chloroethynyl, bromoethynyl and 3-hydroxypropyl. Preferably, the hydrocarbon radical optionally has been provided with a hydroxyl group.


- The acyloxy or acyl group R<sub>3</sub> and R<sub>4</sub> is derived from an organic carboxylic acid containing 1-18 C atoms such as acetic acid, propionic acid, butyric acid, trimethylacetic acid, phenylacetic acid, cyclopentylpropionic acid, phenylpropionic acid, valeric acid, caproic acid, pelargonic acid, lauric acid, palmitic acid, benzoic acid or succinic acid.

- The alkoxyalkyl group R<sub>3</sub> and R<sub>4</sub> preferably is a group having the formula C<sub>n</sub>H<sub>2n+1</sub>OC<sub>m</sub>H<sub>2m</sub> wherein n = 1-4 and m 1-4, like methyloxymethyl, butyloxybutyl or ethyloxymethyl. More preferably n = 1-3 and m = 1-3.

- The alkoxy group R<sub>3</sub> and R<sub>4</sub> is derived from an ether containing 1-12 C atoms such as, for example, methyl ether, ethyl ether, cyclopentyl ether, benzyl ether and tetrahydropyranyl ether.

- If R<sub>3</sub> and R<sub>4</sub> do not together represent a ring system, R<sub>3</sub> is preferably OH, (1-8 C) alkoxy, (1-6 C) acyl, (1-6 C) alkyl optionally provided with a hydroxyl group or alkoxyalkyl with the formula C<sub>n</sub>H<sub>2n+1</sub>OC<sub>m</sub>H<sub>2m</sub> 50 wherein n = 1-3 and m = 1-3 and R<sub>4</sub> is preferably H, (1-6 C) hydrocarbyl optionally provided with a hydroxyl group. If R<sub>3</sub> and R<sub>4</sub> together represent a ring system, preference is given to heterocyclic ring systems containing 5 atoms in the ring, the carbon atom at position 17 of the steroid skeleton being one of these 5 atoms and in particular, to heterocyclic ring systems comprising an oxygen atom in the ring which oxygen atom is bound to the carbon atom at position 17 of the steroid skeleton. The greatest preference is 55 given to the following heterocyclic ring systems:

5



wherein

- 10 the carbon atom which is provided with an \* being the carbon atom in position 17 of the steroid skeleton and X is H<sub>2</sub>, (H, 1-6 C acyloxy), (H, 1-6 C hydrocarbon radical) or 0.

The invention also relates to pharmaceutical products which contain one or more of the compounds according to the invention as the active constituent. The new compounds can be administered orally or parenterally in the usual manner, in combination with pharmaceutical auxiliary substances, in the form of tablets, pills, dragees and other usual administration forms. The dosage forms can be prepared according to known galenical procedures. These pharmaceuticals are prepared according to generally known methods.

15 The administered amount of the compounds according to the present invention may vary within wide ranges, e.g. 50-1000 mg and preferably 100-800 mg during a therapy, which may last 1-10 days. If a one-day therapy is applied the amount administered may vary between e.g. 200 and 1000 mg. If on the other hand a longer therapy, e.g. 5 days, is applied the administered amount each day is lower, e.g. 10-200 mg.

20 The compounds according to the present invention are prepared by successively halogenating, dehydrohalogenating and hydrogenating oestrone 3-methyl ether or a corresponding 18-alkyl (1-3 C) compound at position 16.

25 The halogenation is preferably a bromination, in particular, performed with CuBr<sub>2</sub>. This step is performed at 30-100 °C under atmospheric pressure for 30-180 min.

The dehydrohalogenation is preferably a dehydrobromination, in particular, performed in the presence of lithium bromide, lithium carbonate and dimethylformamide. In general the reaction is terminated after 180 min. The temperature at which the reaction is performed is 60-150 °C. The hydrogenation takes place at 0-80 °C under atmospheric pressure for 15-180 min. in the presence of a catalyst such as Pd/C.

30 The 17-ketone group in the 14β H-oestrone 3-methyl ether or the corresponding 18-alkyl (1-3 C) compound thus obtained is then reduced, for example with NaBH<sub>4</sub>, to a 17α-OH group and the A ring is reduced to a ▲<sup>2</sup>,▲<sup>5(10)</sup> ring by means of a Birch reduction, for example by means of Li/NH<sub>3</sub>/tetrahydrofuran. The 3-methoxy-▲<sup>2</sup>,▲<sup>5(10)</sup>-14βH-oestradien-17α-ol or the corresponding 18-alkyl (1-3 C) compound is then converted with acid, for example oxalic acid, into 14βH-▲<sup>5(10)</sup>-17α-OH-oestren-3-one or the corresponding 35 18-alkyl (1-3 C) compound which, after bromination and dehydrobromination, for example with phenyltrimethylammonium tribromide in pyridine, is converted into 14βH-▲<sup>4</sup>,▲<sup>9</sup>-17α-OH-oestradien-3-one or the corresponding 18-alkyl (1-3 C) compound. Said compound is then ketalized, for example with ethylene glycol/CH<sub>2</sub>Cl<sub>2</sub>/triethyl orthoformate/p-toluenesulphonic acid to 3,3-ethylenedioxy-14βH-▲<sup>5(10)</sup>,▲<sup>9(11)</sup>-oestradien-17α-ol or the corresponding 18-alkyl (1-3 C) compound.

40 The ketalization can also be performed so that compounds are obtained with the groups -OR<sub>6</sub> and -OR<sub>7</sub> in position 3, R<sub>6</sub> being an alkyl group containing 1-4 carbon atoms and R<sub>7</sub> being an alkyl group containing 1-4 carbon atoms or R<sub>6</sub> and R<sub>7</sub> together forming an alkylene group containing 2-5 carbon atoms.

Starting from said compound, the desired substituents can be introduced at positions 17 and 11 in a manner known per se.

45 Thus, after epoxidation of the ▲<sup>5(10)</sup> double bond, for example with m-chloroperbenzoic acid in CH<sub>2</sub>Cl<sub>2</sub> and NaHCO<sub>3</sub>, the R<sub>1</sub> group can be introduced with simultaneous formation of an OH group in position 5α and displacement of the double bond from 9(11) to 9(10) by reaction with an R<sub>1</sub>-containing organometallic compound, such as R<sub>1</sub>MgBr or R<sub>1</sub>Li, for example in the presence of CuCl in tetrahydrofuran. After oxidation of the 17α-OH group, for example by means of an Oppenauer oxidation in cyclohexanone in the presence 50 of aluminium triisopropoxide, a compound according to the present invention is obtained with R<sub>3</sub> = OH by reaction with an R<sub>4</sub>-Li or R<sub>4</sub>-MgX(X can be a halogen atom) and subsequent dehydration and hydrolysis (for example in 80% acetic acid at 75 °C or in 2 N HCl in acetone). It is also possible to dehydrate and hydrolyse immediately after the introduction of R<sub>1</sub>; in that case compounds are obtained with R<sub>3</sub> = OH and R<sub>4</sub> = H.

55 Another method of preparing the compounds according to the present invention is to introduce first the groups in position 17 after the ketalization described above and then only the group R<sub>1</sub> in position 11. In that case the ketalized compound is first oxidized (yielding 17-keto) and reacted with an R<sub>4</sub>-metal compound (yielding 17β-R<sub>4</sub>,17α-OH) in order to be subsequently epoxidized and reacted with R<sub>1</sub>-


MgBr/CuCl. The compound should then be additionally dehydrated and hydrolysed (yielding 3-keto- $\Delta^4$ ). These steps are performed analogously to the corresponding steps already described.

- A variant of the initial introduction of the groups in position 17 and then in position 11 is the following. First a group is introduced at  $17\beta$  under the conditions already described above. This yields a corresponding compound with said group in position  $17\beta$  and OH at  $17\alpha$ . The group  $R_1$  is then introduced in a manner analogous to that already described. If desired, any unsaturated bonds present in the group introduced at  $17\beta$  are then reduced. Dehydration and hydrolysis is then carried out with simultaneous splitting off possible protective groups, such as, for example, tetrahydropyranyl ethers, in the  $17\beta$  substituent to form compounds according to the present invention containing  $R_4$  at  $17\beta$  and OH at  $17\alpha$ . The group to be introduced at  $17\beta$  according to this variant is preferably an alkyl, alkenyl or alkynyl ether. Preference is given to groups with a terminal tetrahydropyranyl ether. In the step in which a part of the group introduced at  $17\beta$  is split off, the tetrahydropyranyl group introduced at  $17\beta$  is then split off to form an alkyl, alkenyl or alkynyl group with a terminal hydroxyl group. If desired, said group can be cyclized with the  $17\alpha$ -OH group.

- Another method of preparing compounds according to the present invention is etherification of the  $17\text{-OH}$  group after the ketalization already described and followed by introduction of the group  $R_1$  and dehydration and hydrolysis.

Yet another method is to introduce a group at position 11 which is such that the group  $R_1$  is formed in the final dehydration and hydrolysis. A suitable group is a phenyldioxane or phenyldioxolane; in the dehydration/hydrolysis step

20



25

is then formed as group  $R_1$ , wherein  $R = H$  or alkyl.


- Yet another method of preparing compounds according to the present invention is to start from 3-methoxy- $14\beta$ H-oestrone and successively perform a Wittig reaction using triphenylphosphonium methylide (yielding 17-methylene), to epoxidize (yielding 17,20-epoxy), to reduce with LiAlH<sub>4</sub> (yielding  $17\beta$ -OH,  $17\alpha$ -CH<sub>3</sub>) and then to introduce group  $R_1$  and to dehydrate/hydrolyse as has already been described. Starting from the 17-methylene compound hydrocarbyl groups comprising a hydroxy group may be introduced at position  $17\alpha$ , whereafter these compounds are converted into compounds according to the present invention in a way as already described.

- After compounds according to the present invention have been obtained with  $R_3$  or  $R_4 = OH$ , said hydroxyl group may, if desired, be esterified or etherified by methods known in order to obtain other compounds according to the invention. Likewise OH groups in hydrocarbyl groups at position  $17\alpha$  or  $17\beta$  may be esterified or etherified or, in addition, be oxidized.

The  $\Delta^{16}$ - and 17-alkylidene compounds according to the present invention are obtained by dehydrating compounds according to the present invention comprising an OH group at position  $17\alpha$  or  $17\beta$ .

- As is evident from the foregoing, the compounds according to the invention are obtained by dehydrating and hydrolysing a compound having the formula:

45



50

55

wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  have the same meaning as has already been described, with the proviso that, if  $R_1$ ,  $R_3$  and/or  $R_4$  represent a group containing oxygen,  $R_1$ ,  $R_3$  and/or  $R_4$  may also be a group containing

oxygen, the oxygen atom being protected by means of a hydrolysable group, and wherein R<sub>6</sub> and R<sub>7</sub> represent an alkyl group containing 1-4 carbon atoms or R<sub>6</sub> and R<sub>7</sub> together represent an alkylene group containing 2-5 carbon atoms, to form compounds according to the present invention. Preferably, the dehydration and the hydrolysis are performed in one step. The temperature at which this step is carried out  
5 is in general 10-90 °C; the reaction time is usually 15 min. up to 16 hours. The dehydration/hydrolysis step is performed in a manner known per se and with agents known per se, such as, for example, with acetic acid or with HCl in acetone or in a mixture of toluene -0.5 N H<sub>2</sub>SO<sub>4</sub>.

The invention is explained more in detail by means of the following examples.

10 Example 1

200 g of CuBr<sub>2</sub> were added in several batches to a solution of 100 g of oestrone 3-methyl ether in a mixture of 800 ml of toluene and 800 ml of methanol. After 1 hour under reflux conditions, the mixture was filtered, diluted with 2 l of water and extracted with ether. The organic layer was washed, dried and  
15 concentrated. The residue was treated with 80%-aqueous ethanol. Yield: 117 g of 3-methoxy-16-bromooestra-1,3,5(10)-trien-17-one as a mixture of 16α and 16β bromides. To this, 170 g of LiBr, 150 g of Li<sub>2</sub>CO<sub>3</sub> and 1 l of dimethylformamide were added. The mixture was stirred for 1 hour under reflux conditions. The mixture was then poured onto 5 l of water and extracted with ethyl acetate. The organic layer was washed several times with H<sub>2</sub>O and then dried and concentrated. The residue was passed  
20 through a silica-gel column using CH<sub>2</sub>Cl<sub>2</sub> as the eluent.

8 g of 10% Pd/C were added to a solution of the product obtained from the eluate in 1.5 l of ethanol. Hydrogenation was then carried out until the calculated quantity of hydrogen had been absorbed. The catalyst was filtered off. The filtrate was concentrated and treated with 0.5 l of 50% aqueous ethanol. The precipitate was filtered and dried under vacuum at 50 °C until a constant weight was obtained. Yield: 75 g  
25 of 14β-3-methoxyestra-1,3,5(10)-trien-17-one; melting point: 109-110 °C.

Example 2

7 g of NaBH<sub>4</sub> were added in batches to a solution of 17 g of the compound obtained in the previous  
30 Example in a mixture of 350 ml of tetrahydrofuran and 350 ml of 96% aqueous ethanol. Stirring was then carried out for 1.5 hours at room temperature. The pH was then brought to 5 by carefully adding 50% aqueous acetic acid. The mixture was then concentrated to a small volume, diluted with water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was successively washed with 1 N NaOH, with 2 N HCl and with water. Drying and concentration were then carried out and the residue was treated with a hexane/ether mixture.  
35 Yield: 15.6 g of (14β,17α)-3-methoxyestra-1,3,5(10)-trien-17-ol; melting point: 102-103 °C. 4.8 g of lithium were added in small batches to a solution of 11 g of this compound in a mixture of 165 ml of tetrahydrofuran, 165 ml of tert.-butyl alcohol and 330 ml of liquid ammonia at -33 °C over a time period of approximately 3 hours. 40 ml of methanol were then added and the ammonia allowed to evaporate. The residue was diluted with water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was washed, dried and  
40 concentrated. The residue was treated with hexane. In this manner, a white solid (melting point: 110-112 °C) was obtained which was dissolved in a mixture of 250 ml of tetrahydrofuran and 100 ml of methanol. A solution of 9 g of oxalic acid dihydrate in 50 ml of water was added to this and stirring was then carried out for 6 hours. 50 g of NaHCO<sub>3</sub> were then added. The mixture was concentrated to a small volume. 250 ml of water were then added, and the product was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed, dried and  
45 concentrated. Yield: 9.4 g of (14β,17α)-17-hydroxyestra-5(10)-en-3-one in the form of a viscous oil; R<sub>f</sub> - (toluene/ethyl acetate 7/3) 0.35. 40 g of phenyltrimethylammonium tribromide were added in batches to a solution of 31 g of this compound in 200 ml of pyridine in 10 min. After stirring for 3 hours at room temperature, the mixture was then poured into 2 l of water and the product was extracted with ethyl acetate. The combined organic layers were washed with 2 N HCl and water. After drying and concentrating, the  
50 residue was treated with diisopropyl ether. After filtration and drying under vacuum, 18 g of (14β,17α)-17-hydroxyestra-4,9-dien-3-one, melting point: 130-131 °C were obtained.

A mixture of 17 g of this compound, 150 ml of CH<sub>2</sub>Cl<sub>2</sub>, 150 ml of ethylene glycol, 50 ml of triethyl orthoformate and 1 g of p-toluenesulphonic acid was stirred for 1 hour at room temperature and then boiled for 10 minutes. The reaction mixture was then treated with 20 g of solid NaHCO<sub>3</sub> and poured into 1 l of 5% NaHCO<sub>3</sub> solution. After extraction with ethyl acetate, and washing, drying and concentration of the organic layer, the residue was passed through a silica-gel column with hexane/ethyl acetate 3/1 (v/v) as eluent. In this manner, 18.5 g of (14β,17α)-17-hydroxy-3,3-ethylenedioxyestra-5(10),9(11)-diene were obtained in the form of a colourless foam; R<sub>f</sub> = 0.56 (hexane/ethyl acetate 1/1).

Example 3

25 g of NaHCO<sub>3</sub> were added to a solution of 18 g of the compound obtained in Example 2 in 100 ml of dry methylene chloride. A solution of 12.5 g of 80% mchloroperbenzoic acid in 75 ml of methylene chloride  
 5 was then added dropwise while stirring at -40 °C in 1 min. The mixture was then stirred on an ice-bath for 30 min. and poured into 500 ml of ice water. The product was extracted in methylene chloride. The organic layer was washed with a 5% NaHCO<sub>3</sub> solution and with water, and dried and concentrated. The residue was rapidly chromatographed on SiO<sub>2</sub> using hexane/ethyl acetate 2/1 (v/v) as eluent. This yielded 8.5 g of  
 10 (5 $\alpha$ ,10 $\alpha$ ,14 $\beta$ ,17 $\alpha$ )-3,3-thylene-dioxy-5,10-epoxyoestr-9(11)-en-17-ol in the form of a foam; R<sub>f</sub> 0.48 (hexane/ethyl acetate 1/1).

A Grignard reagent was prepared in 200 ml of dry tetrahydrofuran by reacting 24 g of p-bromo-N,N-dimethylaniline and 3 g of magnesium turnings. 300 mg of CuCl were added to this, followed by dropwise addition of 8.5 g of the epoxide in 30 ml of dry tetrahydrofuran. After stirring for 30 minutes at room temperature, the reaction mixture was poured into 1.5 l of a 10% NH<sub>4</sub>Cl solution and extracted in ethyl acetate. The organic layer was washed, dried and concentrated. The residue was chromatographed on SiO<sub>2</sub> using hexane/ethyl acetate 1/1 as eluent. After crystallization from diisopropyl ether, 6.6 g of  
 15 (5 $\alpha$ ,11 $\beta$ ,14 $\beta$ ,17 $\alpha$ )-3,3-ethylenedioxy-11-(4-dimethylaminophenyl)-oestr-9-ene-15,17-diol (melting point: 107-109 °C) were obtained.

A solution of 1.5 g of this compound in 25 ml of 80% aqueous acetic acid was heated for 45 min. (75-  
 20 80 °C). The mixture was cooled with ice water and neutralized by adding concentrated NH<sub>4</sub>OH. The product was extracted with ethyl acetate. The organic layer was washed, dried and concentrated. After treating the residue with diisopropyl ether, and crystallizing, filtering and drying the precipitate, 0.75 g of (14 $\beta$ ,17 $\alpha$ )-11-(4-dimethylaminophenyl)-17-hydroxyoestra-4,9-dien-3-one (melting point: 166-167 °C;  $\alpha_D$  - (dioxane) = +212 °; R<sub>f</sub> (hexane/ethyl acetate 1/1) = 0.32) was obtained.  
 25

Example 4

A solution of 4.8 g of (5 $\alpha$ ,11 $\beta$ ,14 $\beta$ ,17 $\alpha$ )-3,3-ethylenedioxy-11-(4-dimethylaminophenyl)-oestr-9-ene-5,17-diol in a mixture of 200 ml of dry toluene, 40 ml of cyclohexanone and 6 g of aluminium isopropoxide was  
 30 kept for 3 hours under reflux conditions. The mixture was cooled, diluted with 200 ml of ethyl acetate and washed several times with a 75% w/v solution of Seignette salt. The organic layer was finally washed with water, dried and concentrated. The residue was passed through a silica-gel column with a hexane/ethyl acetate gradient (10/1-1/2) as eluent. The product was treated with a mixture of hexane and diisopropyl ether (1/2 v/v). The precipitate was filtered and dried. Yield: 3.1 g of (5 $\alpha$ ,11 $\beta$ ,14 $\beta$ )-3,3-ethylenedioxy-5-hydroxy-11-(4-dimethylaminophenyl)-oestr-9-en-17-one (melting point: 158-160 °C).

A solution of 3 ml of 1.5 M CH<sub>3</sub>Li-LiBr complex in ether was added dropwise to a solution of 2 g of this compound in 25 ml of dry tetrahydrofuran at -10 °C. After stirring for 10 min., the mixture was poured into 100 ml of ice water. The product was extracted with ethyl acetate. The organic layer was washed, dried and concentrated. The residue was chromatographed on silica gel with a toluene/ethyl acetate gradient (10/1 → 1/2) as eluent. Yield: 1.2 g of amorphous (5 $\alpha$ ,11 $\beta$ ,14 $\beta$ ,17 $\alpha$ )-3,3-ethylenedioxy-11-(4-dimethylaminophenyl)-17-methyoestr-9-ene-5,17-diol, R<sub>f</sub> = 0.42 (hexane/ethyl acetate 1/1). A solution of 1.2 g of this compound in 25 ml of 80% aqueous acetic acid was heated for 45 min. at 75 °C. After cooling in ice water and neutralizing with concentrated NH<sub>4</sub>OH, the product was extracted in ethyl acetate. The organic layer was washed, dried and concentrated. The residue was treated with 20 ml of diisopropyl ether.  
 40 After crystallization the precipitate is filtered and dried. Yield: 0.73 g of (11 $\beta$ ,14 $\beta$ ,17 $\alpha$ )-11-(4-dimethylaminophenyl)-17-hydroxy-17-methyoestra-4,9-dien-3-one (melting point = 109-111 °C;  $\alpha_D$  - (dioxane) = +213° and R<sub>f</sub> = 0.40 (hexane/ethyl acetate 1/1)). In an analogous way the corresponding 17 $\beta$ -ethynyl (m.p. 106-107 °C) and 17 $\beta$ -1-propynyl (R<sub>f</sub> = 0.30 toluene/ethyl acetate 7/3 v/v) compounds were prepared.  
 45

The above 17-keto compound with m.p. 158-160 °C was reacted with the Grignard reagent of 2-(2-bromo-ethyl)-1,3-dioxolane. The product obtained was converted with 80% acetic acid at 80 °C into (11 $\beta$ ,14 $\beta$ ,17 $\alpha$ )-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-oxopropyl)-estra-4,9-dien-3-one, cyclic hemiacetal (R<sub>f</sub> = 0.30 hexane/ethylacetate). As a byproduct (11 $\beta$ ,14 $\beta$ ,17 $\alpha$ ,5'R)-11-(4-dimethylaminophenyl)-4',5'-dihydrospiro[estra-4,9-diene-17,2'(3'H)-5'-acetoxy-furan]-3-one (m.p. 199-200 °C) was obtained.  
 50

Example 5

29 g of dicyclohexylcarbodiimide were added to a solution of 16.5 g of the compound finally obtained in

Example 2 in a mixture of 60 ml of toluene, 50 ml of dimethyl sulphoxide and 20 ml of pyridine. 5 ml of dichloroacetic acid were added dropwise at 5 °C in 10 min. A further amount of approximately 10 ml of pyridine was then added to keep the pH at 7. After stirring for 45 min., the excess of oxidant was destroyed by adding 5 ml of methanol dropwise, followed by a solution of 11 g of oxalic acid dihydrate in 50 ml of 5 methanol. After stirring for 30 min., 500 ml of ether were added. After 30 min., the precipitate was filtered, the filtrate was washed several times with water, a 10% NaHCO<sub>3</sub> solution and Water, and then dried and concentrated. The residue was chromatographed on SiO<sub>2</sub> with hexane/ethyl acetate 4/1 (v/v) as eluent. After treatment with hexane/diisopropyl ether, 9.8 g of (14β)-3,3-ethylenedioxoestra-5(10),9(11)-dien-17-one (melting point: 110-112 °C) were obtained.

10 20 ml of a 2 M propyl magnesium chloride solution in ether were added to a solution of 7.5 g of propargyl alcohol tetrahydropyranyl ether in 50 ml of dry tetrahydrofuran. After stirring for 10 min., a solution of 4.75 g of the oestradienone compound prepared last in 20 ml of dry tetrahydrofuran was added to this. After stirring for 6 hours at room temperature, the reaction mixture was poured into 500 ml of a 10% NH<sub>4</sub>Cl solution. The product was extracted with ethyl acetate. After washing, drying and concentrating the 15 organic layer, the residue was chromatographed on silica gel using a hexane/ethyl acetate gradient (5/1 → 1/1) as eluent. Treatment of the product with diisopropyl ether/hexane 1/1 (v/v) yielded 4.1 g of (14β,17α)-3,3-ethylenedioxo-17-(3-tetrahydropyranyloxyprop-1-ynyl)oestra-5(10),9(11)-dien-17-ol (melting point: 130-132 °C).

20 A solution of 4 g of 85% m-chloroperbenzoic acid in 100 ml of CH<sub>2</sub>Cl<sub>2</sub> was added to a cooled (-60 °C) 20 solution of 8.5 g of this compound and 10 g of solid NaHCO<sub>3</sub> in 100 ml of CH<sub>2</sub>Cl<sub>2</sub>. The mixture was stirred at 0 °C for 45 min. and then diluted with 250 ml of a 5% NaHCO<sub>3</sub> solution. The product was extracted in CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed several times with water. After drying and concentrating the residue was chromatographed on silica gel with a hexane/ethyl acetate gradient (4/1 → 1/1) as eluent. Yield: 5.8 g of amorphous (5α,10α,14β,17α)-3,3-ethylenedioxo-5,10-epoxy-17-(3-tetrahydropyranyloxyprop-1-ynyl)-25 oestr-9(11)-en-17-ol; R<sub>f</sub> = 0.63 (hexane/ethyl acetate 1/1).

30 A solution of 5.5 g of this compound in 20 ml of dry tetrahydrofuran was added to a Grignard reagent which had been prepared starting from 1.3 g of magnesium and 10.5 g of p-bromo-N,N-dimethylaniline in 60 ml of dry tetrahydrofuran and to which 300 mg of CuCl had been added. Stirring was then carried out for an additional one hour and the reaction mixture was then poured into 500 ml of a 10% NH<sub>4</sub>Cl solution. After 30 extraction with ethyl acetate and washing, drying and concentrating the organic phase, the residue was chromatographed on silica gel using hexane/ethyl acetate 3/2 as eluent. After treatment with hexane-/diisopropylether 1/2 (v/v), 4.5 g of (5α,11β,14β,17α)-3,3-ethylenedioxo-11-(4-dimethylaminophenyl)-17-(3-tetrahydropyranyloxyprop-1-ynyl)-oestr-5-(10)-ene-5,17-diol, melting point: 161-162 °C were obtained. A solution of 2 g thereof in a mixture of toluene-/ethanol 1/1 was hydrogenated in the presence of 200 mg of 35 5% pd-BaSO<sub>4</sub> until the theoretical quantity of 2 equivalents of hydrogen had been absorbed. The catalyst was filtered off and the filtrate concentrated. The residue was dissolved in 40 ml of 80% acetic acid and heated to 80 °C for 45 min. After cooling, the mixture was neutralized by addition of conc. NH<sub>4</sub>OH and extracted with ethyl acetate. After washing, drying and concentrating the organic phase, the residue was chromatographed on silica gel with CH<sub>2</sub>Cl<sub>2</sub>/acetone 1/1 as eluent. Yield: 1.2 g of amorphous (11β,14β,17α)-40 11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-oestra-4,9-dien-3-one, R<sub>f</sub> = 0.42 (CH<sub>2</sub>Cl<sub>2</sub>-acetone 1/1) and α<sub>D</sub> = +194° (c = 1, dioxane).

45 Immediate dehydration and hydrolysis of the above 11-(4-dimethylaminophenyl)-17-(3-tetrahydropyranyloxyprop-1-ynyl) compound yielded the corresponding 17β-(3-hydroxyprop-1-ynyl) compound (α<sub>D</sub> + 279° dioxane).

50 600 mg of p-toluenesulphonyl chloride were added to a solution of 1.2 g of this compound in 15 ml of pyridine. After stirring for 6 hours, 100 ml of H<sub>2</sub>O were added. After extraction with ether, the organic layer was washed several times with H<sub>2</sub>O, dried and concentrated. The residue was chromatographed on silica gel with toluene/acetone 2/1 as eluent. After treatment with hexane/isopropyl ether 1/1, 0.7 g of (11β,14β,17α)-11-(4-dimethylaminophenyl)-4',5'-dihydrospiro[oestra-4,9-diene-17,2'(3'H)-furan]-3-one (melting point: 172-174 °C) was obtained.

55 To a solution of 500 mg of this compound in 10 ml CH<sub>2</sub>Cl<sub>2</sub> and 1 g CaO a solution of 700 mg I<sub>2</sub> in 10 ml CH<sub>3</sub>OH was added. After stirring for 3 h. at room temperature the mixture was poured onto 200 ml 5% NaHSO<sub>3</sub> and extracted with ethyl acetate. After washing, drying and evaporating the organic phase the residue was chromatographed on silica gel. This yielded 140 mg of the corresponding 4-methylamino-phenyl compound (m.p. 120-122 °C).

In an analogous way as described for the 4-dimethylaminophenyl compound the corresponding 4-diethylaminophenyl compound was obtained (m.p. 135-137 °C).

To a solution of the 17α-hydroxy-17β-(3-hydroxypropyl) compound with α<sub>D</sub> + 194 °C in a mixture of

toluene (3 ml),  $\text{CH}_2\text{Cl}_2$  (3 ml), dimethylsulphoxide (2 ml) and pyridine (0.4 ml) 0.7 g of dicyclohexylcarbodiimide was added. Subsequently 0.11 ml dichloro-acetic acid was added dropwise at 0 °C. After 0.5 h. 0.1 ml of methanol was added dropwise followed by 0.26 g oxalic acid in 1 ml of methanol. After stirring for 15 min. the mixture was diluted with 30 ml of ether. The precipitate was filtered off and the organic phase was washed, dried and concentrated. The residue was chromatographed on silica gel. This yielded 250 mg of ( $11\beta,14\beta$ )-11-(4-dimethylaminophenyl)-17-(3-hydroxypropyl)estra-4,9,16-trien-3-one ( $R_f = 0.29$  hexane/ethylacetate 1/1 v/v) and some ( $11\beta,14\beta$ )-11-(4-dimethylaminophenyl)-17-(3-hydroxypropylidene)-estra-4,9-dien-3-one ( $R_f 0.29$  hexane/ethylacetate 1/1 v/v).

Starting from 18-methyloestrone 3-methylether examples 1, 2 and 5 were repeated in an analogous way yielding ( $11\beta,14\beta,17\alpha$ )-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-18-methylestra-4,9-dien-3-one ( $R_f = 0.17$ ; toluene/acetone 3/1 v/v) and ( $11\beta,14\beta,17\alpha$ )-11-(4-dimethylaminophenyl)-18-methyl-4',5'-dihydrospiro[estra-4,9-dien-17,2'(3'H)-furan]-3-one (m.p. 151-152 °C).

#### Example 6

3 g of a 50% dispersion of sodium hydride in mineral oil were added to a solution of 5 g of the compound finally obtained in Example 2 in a mixture of 50 ml of tetrahydrofuran and 20 ml of dimethyl sulphoxide. After stirring for 5 min., 5 ml of ethyl iodide were added. The reaction, which was followed by means of thin-layer chromatography, had proceeded to completion after 3 hours. The mixture was poured into water and the product was extracted with ether. After washing, drying and concentrating of the organic solvent, the residue was chromatographed on silica gel using hexane/ethyl acetate 95/5 (v/v) as eluent. Yield: 5.1 g of ( $14\beta,17\alpha$ )-3,3-ethylenedioxy-17-ethoxyestra-5(10),9(11)-diene in the form of a colourless oil;  $R_f 0.34$  (hexane/ethyl acetate).

7 g of sodium bicarbonate were added to a solution of 4.2 g of this compound in 50 ml of dry methylene chloride and then a solution of 2 g of 80% m-chloroperbenzoic acid in 25 ml of methylene chloride was added at -40 °C. After stirring for 30 min. at 0 °C, the mixture was poured into 200 ml of a 5% sodium bicarbonate solution. After extraction with methylene chloride, the organic phase was washed, dried and concentrated. The residue was chromatographed on silica gel using hexane/ethyl acetate 9/1 as eluent. The product obtained was treated with the Grignard reagent p-dimethylaminophenylmagnesium bromide in the presence of 150 mg of CuCl in 40 ml of tetrahydrofuran. After stirring for 30 min. at room temperature, the reaction mixture was poured into 300 ml of a 10% NH<sub>4</sub>Cl solution. After extraction with ether, the organic phase was washed, dried and concentrated. The residue was chromatographed on silica gel using hexane/ethyl acetate 3/2 as eluent. Yield: 2.4 g of ( $5\alpha,11\beta,14\beta,17\alpha$ )-3,3-ethylenedioxy-11-(4-dimethylaminophenyl)-17-ethoxyoestr-9-en-5-ol in the form of a colourless oil;  $R_f 0.59$  (hexane/ethyl acetate 1/1, v/v. A solution of 2.2 g of this compound in 50 ml of 80% acetic acid was heated for 1 hour at 80 °C. After cooling, the reaction mixture was neutralized with concentrated ammonia. After extraction with ether, the organic phase was washed, dried and concentrated. The residue was chromatographed on silica gel using hexane/acetone 9/1 as eluent. Yield: 1.3 g of ( $11\beta,14\beta,17\alpha$ )-11-(4-dimethylaminophenyl)-17-ethoxyoestr-4,9-dien-3-one in the form of a yellowish oil;  $R_f = 0.33$  (hexane/acetone 9/1).

In an analogous way the corresponding 17 $\alpha$ -butyloxy ( $\alpha_D$  163 °, dioxane) and 17 $\alpha$ -hexyloxy ( $\alpha_D$  153 °, dioxane) compounds were prepared.

#### Example 7

300 mg of CuCl were added to the Grignard reagent prepared from 4.5 g of 4-(5,5-dimethyl-1,3-dioxan-2-yl)-phenyl bromide and 0.8 g of Mg in 15 ml of dry tetra-hydrofuran, followed by 2.2 g of ( $5\alpha,10\alpha,14\beta,17\alpha$ )-3,3-ethylenedioxy-5,10-epoxyoestr-9(11)-en-17-ol, prepared in Example 3, in 10 ml of dry tetrahydrofuran. After stirring for 1 hour at room temperature, the mixture was poured into 200 ml of saturated NH<sub>4</sub>Cl solution. After extraction with ethyl acetate and washing, drying and concentrating the organic phase, the residue was chromatographed on silica gel using hexane/ethyl acetate 1/1 as eluent. After crystallization from diisopropyl ether, 1.7 g of ( $5\alpha,11\beta,14\beta,17\alpha$ )-3,3-ethylenedioxy-11-[4-(5,5-dimethyl-1,3-dioxan-2-yl)phenyl]oestr-9-ene-5,17-diol were obtained; melting point: 176-177 °C. A solution of 1.5 g of this compound in 30 ml of 80% acetic acid was heated for 45 min. at 75 °C. After cooling and neutralizing by concentrated NH<sub>4</sub>OH, the product was extracted with ethyl acetate. The organic phase was washed, dried and concentrated. The residue was chromatographed on silica gel using hexane/ethyl acetate 1/1 as eluent. After crystallization from diisopropyl ether, 0.6 g of ( $11\beta,14\beta,17\alpha$ )-11-(4-formylphenyl)-17-hydroxyoestra-4,9-dien-3-one was obtained; melting point: 153-155 °C.

Example 8

Oxidation of 1.25 g of the oestrenediol compound prepared in Example 7 with 2 g of aluminium isopropoxide in a mixture of 60 ml of toluene and 10 ml of cyclohexanone under reflux conditions yielded, 5 after crystallization from ether/hexane, 0.95 g of ( $5\alpha,11\beta,14\beta$ )-3,3-ethylenedioxy-11-[4-(5,5-dimethyl-1,3-dioxan-2-yl)-phenyl]-5-hydroxyoestr-9-en-17-one, melting point: 158-160 °C. This product was ethinylated with lithium acetylidyne in tetrahydrofuran, and 0.4 g of the material obtained was dissolved in 5 ml of 80% aqueous acetic acid and heated for 1 hour at 75 °C. After cooling and neutralizing with a concentrated NH<sub>4</sub>OH solution, the product was extracted with ether. After washing, drying and concentrating the organic 10 layer, the residue was chromatographed on silica gel with hexane/ethyl acetate 1/1 as eluent. After crystallization from diisopropyl ether, 210 mg of ( $11\beta,14\beta,17\beta$ )-11-(4-formylphenyl)-17-hydroxypregna-4,9-dien-20-yn-3-one were obtained; melting point: 223-225 °C.

In an analogous way to that described in Example 7 and this Example the corresponding 11-(4-acetylphenyl) compound (m.p. 179-180 °C) was prepared.

15 In an analogous way to that described in Example 7 and the oxidation step in this Example, followed by incorporation of the 3-tetrahydropyranoyloxyprop-1-ynyl group at position 17 and cyclizing as described in Example 5, ( $11\beta,14\beta,17\alpha$ )-11-(4-acetylphenyl)-4',5'-dihydrospiro[oestra-4,9-diene-17,2'(3'H)-furan]-3-one ( $\alpha_D$  165 ° in dioxane) was obtained.

Example 9

A mixture of 4 g  $14\beta$ -oestrone-3-methylether, 2.2 g LiNH<sub>2</sub> and 38 g methyltriphenylphosphoniumbromide in 130 ml toluene and 10 ml dimethylsulphoxide was heated at 60 °C for 16 h. Subsequently, the mixture was poured out into 300 ml ice-water and extracted with ethylacetate. Purification by chromatography 25 yielded the corresponding 17-methylene compound. To a solution of 11.2 g of this compound in 200 ml dry tetrahydrofuran 100 ml of 0.5 molar 9-borabicyclononane in tetrahydrofuran was added dropwise at room temperature. The mixture was stirred for 1 h. at room temperature. Subsequently 80 ml of H<sub>2</sub>O, 80 ml of 3 N NaOH and 40 ml 30% H<sub>2</sub>O<sub>2</sub> were added dropwise after each other. After 2 h. this was poured into water and the product was extracted by means of ethyl acetate. The residue obtained after washing, drying and 30 evaporation was triturated with diisopropylether yielding the corresponding  $17\alpha$ -hydroxymethyl compound. This compound was converted into the 3,3-ethylenedioxy-▲<sup>5(10),▲9(11)</sup> derivative as described in Example 2. A part of this derivative (2.4 g) was converted into the  $17\alpha$ -methoxymethyl derivative by dissolving it in a mixture of 84 ml tetrahydrofuran and 15 ml dimethylsulphoxide, and reacting with 4.8 g 50% NaH dispersion in oil and 3.6 ml methyl iodide. After stirring for 16 h at room temperature, the mixture was 35 poured into ice-water, extracted with ether, washed, dried, evaporated and chromatographed.

Analogously to the procedure described in Example 3 these  $17\alpha$ -hydroxymethyl and  $17\alpha$ -methoxymethyl compounds were converted into ( $11\beta,14\beta,17\alpha$ )-11-(4-dimethylaminophenyl)-17-hydroxymethyl-estra-4,9-dien-3-one (m.p. 185 °C) and ( $11\beta,14\beta,17\alpha$ )-11-(4-dimethylaminophenyl)-17-methoxymethyl-estra-4,9-dien-3-one ( $\alpha_D$  = +214 ° c = 1, dioxane) respectively. The first compound was reacted With acetic 40 acid anhydride in pyridine at room temperature yielding the corresponding acetic acid ester (m.p. 142 °C).

Example 10

A mixture of 60 g of K-t.butylate and 256 g ethyltriphenylphosphonium iodide in 1200 ml tetrahydrofuran 45 was stirred for 0.5 h at room temperature. Subsequently 87 g of  $14\beta$ -oestrone-3-methylether in 600 ml of tetrahydrofuran was added. The mixture was left at reflux temperature for 10 h. and subsequently poured out into 6 l of H<sub>2</sub>O and extracted with ethyl acetate. Chromatography of the product on silica gel yielded 104 g of the corresponding 17-Z/E-ethylidene (5/1) compound. To a solution of 106 ml 10 M BH<sub>3</sub>.dimethylsulphide complex in 400 ml of tetrahydrofuran 131 ml 1,4-cyclooctadiene was added dropwise 50 at °C. After keeping this 1 h. at reflux temperature 140 g of the above 17-Z/E-ethylidene product in 400 ml of tetrahydrofuran was added at room temperature. Subsequently this was kept at reflux temperature for 3 h. Then 484 ml 3 N NaOH and 484 ml 30% H<sub>2</sub>O<sub>2</sub> were added successively. The mixture was poured into 7 l 10% Na<sub>2</sub>SO<sub>3</sub> solution and extracted with ethylacetate. Chromatography yielded 17 g of ( $14\beta,17\alpha,20S$ )-20-hydroxy-pregna-1,3,5(10)-triene and 70 g of ( $14,17\alpha,20R$ )-20-hydroxy-pregna-1,3,5(10)-triene. These 55 compounds were converted into ( $11\beta,14\beta,17\alpha,20S$ )-11-(4-dimethylaminophenyl)-20-hydroxy-pregna-4,9-dien-3-one (m.p. 210-212 °C) and ( $11\beta,14\beta,17\alpha,20R$ )-11-(4-dimethylaminophenyl)-20-hydroxy-pregna-4,9-dien-3-one ( $\alpha_D$  = +166 ° c = 1, dioxane) by methods described in Examples 2 and 3.

Oxidation of the 20R-compound yielded the corresponding 20-keto compound ( $\alpha_D$  = 215° c = 1,

dioxane). Esterification of the 20R- and 20S-compound by means of propionic acid anhydride yielded the corresponding 20-R-propionate ( $\alpha_D = 176^\circ$  c = 1, dioxane) and 20-S-propionate ( $\alpha_D = +227^\circ$  c = 1, dioxane) respectively.

5    Example 11

The following compounds were tested in a pregnancy interruption test and an antiglucocorticoid test:  
 compound 1: (11 $\beta$ ,14 $\beta$ ,17 $\alpha$ )-11-(4-dimethylaminophenyl)-4',5'-dihydrospiro[oestra-4,9-diene-17,2'(3'H)-furan]-3-one (according to the present invention).  
 10    compound 2: (11 $\beta$ ,17 $\beta$ )-11-(4-dimethylaminophenyl)-17-hydroxy-17-(1-propynyl)-oestra-4,9-dien-3-one.  
 compound 3: (11 $\beta$ ,13 $\alpha$ ,17 $\alpha$ )-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxy-propyl)-oestra-4,9-dien-3-one.

The pregnancy interruption test was carried out in a similar way as described in Contraception 1981, Vol. 24, No. 3, page 289-299: pregnant rats were given 2 times a day an amount "X" of one of the above 15 compounds orally from the 6th until the 10th day of the pregnancy. At the 15th day the rats were sacrificed and the following figure was determined:

$$20 \quad P = \frac{(\text{total amount of implantation points} - \text{total amount of living embryo's})}{\text{total amount of implantation points}} \cdot 100$$

The antiglucocorticoid test was performed as follows. Young male rats were given orally 5  $\mu\text{g}/\text{day}$  of 25 dexamethasone (group 1) or 5  $\mu\text{g}/\text{day}$  of dexamethasone + 1 mg/day of one of the above compounds (group 2) or nothing (only vehicle medium) (group 3) during 7 days. The following day the rats were sacrificed, the thymus of the rats was weighed and the following figure was calculated:

$$30 \quad Q = \frac{\text{thymus weight group 2} - \text{thymus weight group 1}}{\text{thymus weight group 3} - \text{thymus weight group 1}}$$

(the lower Q the lower is the antiglucocorticoid activity).

35    The results are presented in the following Table:

Table


	P at X = 0.5 mg	P at X = 1 mg	Q
compound 1	96	100	5
compound 2	-	100	92
compound 3	49	100	70

45

**Claims**


**Claims for the following Contracting States : AT, BE, CH/LI, DE, FR, GB, IT, NL, SE**

50    1. 11-arylstroid derivatives, characterized in that these derivatives have the following structure:



wherein:

15       $R_1$  is a homocyclic or heterocyclic aryl group having one of the following substituents: an optionally saturated or unsaturated, branched or unbranched hydrocarbon radical containing 1-10 carbon atoms, the hydrocarbon radical being optionally provided with a hydroxyimino, oxo and/or hydroxyl group; or a




25      group, where X and Y are each separately H or a hydrocarbon (1-4 C) radical or are together a hydrocarbon (2-6 C) radical;

30       $R_2$  is an alkyl group containing 1-4 carbon atoms;

35       $R_3$  is H, OH, a saturated or unsaturated hydrocarbon radical containing 1-8 carbon atoms, optionally provided with one or more hydroxyl, azido, nitrile, oxo and/or halogen groups, or is an (1-18 C) acyloxy or (2-8 C) alkoxyalkyl or (1-18 C) acyl or (1-12 C) alkoxy group;

40       $R_4$  is H, OH, a saturated or unsaturated hydrocarbon group containing 1-8 carbon atoms, optionally provided with one or more hydroxyl, azido, nitrile, oxo and/or halogen groups, or is an (1-18 C) acyloxy or (2-8 C) alkoxyalkyl or (1-18 C) acyl or (1-12 C) alkoxy group; or  $R_3$  and  $R_4$  together form a ring system or an alkylidene group having 1-6 carbon atoms and the dotted line represents an optional bond between the carbon atoms 16 and 17 of the steroid skeleton, with the proviso that  $R_3$  or  $R_4$  is absent if said bond between said carbon atoms 16 and 17 is present.

2. Compounds according to claim 1, characterized in that  $R_1$  is an aryl group containing as substituent an acyl group having 1-4 carbon atoms or a group



wherein X and Y separately are H or a saturated alkyl group having 1-3 carbon atoms.

3. Compounds according to claim 1 or 2, characterized in that  $R_2$  is methyl or ethyl.
- 50      4. Compounds according to claims 1-3, characterized in that  $R_3$  represents OH, (1-8 C) alkoxy, (1-6 C) acyl, (1-6 C) alkyl optionally provided with a hydroxyl group, or alkoxyalkyl with the formula  $C_nH_{2n+1}OC_mH_{2m}$  wherein n = 1-3 and m = 1-3.
- 55      5. Compounds according to claims 1-4, characterized in that  $R_4$  represents H or (1-6 C) hydrocarbyl optionally provided with a hydroxyl group.
6. Compounds according to claims 1-3, characterized in that  $R_3$  and  $R_4$  together form a heterocyclic ring


system containing 5 atoms in the ring.

7. Method for preparing compounds according to claim 1, characterized in that a compound having the formula:

5

10

15



20 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> have the same meaning as in claim 1, with the proviso that if R<sub>1</sub>, R<sub>3</sub> and/or R<sub>4</sub> represent an oxygen-containing group, R<sub>1</sub>, R<sub>3</sub> and/or R<sub>4</sub> may also be an oxygen-containing group, the oxygen atom being protected by means of a hydrolysable group, and wherein R<sub>6</sub> and R<sub>7</sub> represent an alkyl group containing 1-4 carbon atoms or R<sub>6</sub> and R<sub>7</sub> together represent an alkylene group containing 2-5 carbon atoms, is dehydrated and hydrolysed to form compounds according to claim 1 and that subsequently, if desired, compounds comprising an OH group at position 17α or 17β are dehydrated, esterified or etherified and, if desired, compounds comprising a hydrocarbon radical provided with one or more hydroxyl groups are esterified, etherified or oxidized.

- 25
8. Pharmaceutical composition comprising a compound according to claim 1 as the active ingredient.

30

#### Claims for the following Contracting States : ES, GR

- 35 1. Method for preparing 11-aryl steroid derivatives, having the following structure:


40

45

50


wherein:  
R<sub>1</sub> is a homocyclic or heterocyclic aryl group having one of the following substituents: an optionally saturated or unsaturated, branched or unbranched hydrocarbon radical containing 1-10 carbon atoms, the hydrocarbon radical being optionally provided with a hydroxyimino, oxo and/or hydroxyl group; or a

55




group; where X and Y are each separately H or a hydrocarbon (1-4 C) radical or are together a hydrocarbon (2-6 C) radical;

- R<sub>2</sub> is an alkyl group containing 1-4 carbon atoms;  
 R<sub>3</sub> is H, OH, a saturated or unsaturated hydrocarbon radical containing 1-8 carbon atoms, optionally provided with one or more hydroxyl, azido, nitrile, oxo and/or halogen groups, or is an (1-18 C) acyloxy or (2-8 C) alkoxyalkyl or (1-18 C) acyl or (1-12 C) alkoxy group;  
 5 R<sub>4</sub> is H, OH, a saturated or unsaturated hydrocarbon group containing 1-8 carbon atoms, optionally provided with one or more hydroxyl, azido, nitrile, oxo and/or halogen groups, or is an (1-18 C) acyloxy or (2-8 C) alkoxyalkyl or (1-18 C) acyl or (1-12 C) alkoxy group; or R<sub>3</sub> and R<sub>4</sub> together form a ring system or an alkylidene group having 1-6 carbon atoms and the dotted line represents an optional bond between the carbon atoms 16 and 17 of the steroid skeleton, with the proviso that R<sub>3</sub> or R<sub>4</sub> is absent if said bond between said carbon atoms 16 and 17 is present,  
 10 characterized in that a compound having the formula:



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> have the previously given meanings , with the proviso that if R<sub>1</sub>, R<sub>3</sub> and/or R<sub>4</sub> represent an oxygen-containing group, R<sub>1</sub>, R<sub>3</sub> and/or R<sub>4</sub> may also be an oxygen-containing group, the oxygen atom being protected by means of a hydrolysable group, and wherein R<sub>6</sub> and R<sub>7</sub> represent an alkyl group containing 1-4 carbon atoms or R<sub>6</sub> and R<sub>7</sub> together represent an alkylene group containing 2-5 carbon atoms, is dehydrated and hydrolysed to form the desired compounds and that subsequently, if desired, compounds comprising an OH group at position 17α or 17β are dehydrated, esterified or etherified and, if desired, compounds comprising a hydrocarbon radical provided with one or more hydroxyl groups are esterified, etherified or oxidized.

- 35 2. Method for preparing 11-aryl steroid derivatives according to claim 1, characterized in that R<sub>1</sub> is an aryl group containing as substituent an acyl group having 1-4 carbon atoms or a group




45 wherein X and Y separately are H or a saturated alkyl group having 1-3 carbon atoms.

3. Method for preparing 11-aryl steroid derivatives according to claim 1 or 2, characterized in that R<sub>2</sub> is methyl or ethyl.  
 50 4. Method for preparing 11-aryl steroid derivatives according to claims 1-3, characterized in that R<sub>3</sub> represents OH, (1-8 C) alkoxy, (1-6 C) acyl, (1-6 C) alkyl optionally provided with a hydroxyl group, or alkoxyalkyl with the formula C<sub>n</sub>H<sub>2n+1</sub>OC<sub>m</sub>H<sub>2m</sub> wherein n = 1-3 and m = 1-3.  
 55 5. Method for preparing 11-aryl steroid derivatives according to claims 1-4, characterized in that R<sub>4</sub> represents H or (1-6 C) hydrocarbyl optionally provided with a hydroxyl group.  
 6. Method for preparing 11-aryl steroid derivatives according to claims 1-3, characterized in that R<sub>3</sub> and R<sub>4</sub> together form a heterocyclic ring system containing 5 atoms in the ring.

## Revendications


Revendications pour les Etats contractants suivants : AT, BE, CH/LI, DE, FR, GB, IT, NL, SE

1. Dérivés stéroïdiques arylés à la position 11, caractérisés en ce que ces dérivés ont la structure suivante :



dans laquelle

R<sub>1</sub> est un groupe aryle homocyclique ou hétérocyclique ayant l'un des substituants suivants : un radical hydrocarboné facultativement saturé ou insaturé, ramifié ou non ramifié, contenant 1 à 10 atomes de carbone, le radical hydrocarboné comportant facultativement un groupe hydroximino, oxo et/ou hydroxyle ; ou un groupe




où X et Y sont chacun séparément H ou un radical hydrocarboné (C<sub>1</sub>-C<sub>4</sub>) ou bien forment ensemble un radical hydrocarboné (C<sub>2</sub>-C<sub>6</sub>) ;

R<sub>2</sub> est un groupe alkyle contenant 1 à 4 atomes de carbone ;

R<sub>3</sub> est H, OH, un radical hydrocarboné saturé ou insaturé contenant 1 à 8 atomes de carbone, comportant facultativement un ou plusieurs groupes hydroxyle, azido, nitrile, oxo et/ou halogéno, ou bien est un groupe acyloxy (C<sub>1</sub>-C<sub>18</sub>) ou alcoxyalkyle (C<sub>2</sub>-C<sub>8</sub>) ou acyle (C<sub>1</sub>-C<sub>18</sub>) ou alcoxy (C<sub>1</sub>-C<sub>12</sub>) ;

R<sub>4</sub> est H, OH, un radical hydrocarboné saturé ou insaturé contenant 1 à 8 atomes de carbone, comportant facultativement un ou plusieurs groupes hydroxyle, azido, nitrile, oxo et/ou halogéno, ou bien est un groupe acyloxy (C<sub>1</sub>-C<sub>18</sub>) ou alcoxyalkyle (C<sub>2</sub>-C<sub>8</sub>) ou acyle (C<sub>1</sub>-C<sub>18</sub>) ou alcoxy (C<sub>1</sub>-C<sub>12</sub>) ; ou bien R<sub>3</sub> et R<sub>4</sub> forment ensemble un système cyclique ou un groupe alkylidène ayant 1 à 6 atomes de carbone et le trait en pointillé représente une liaison facultative entre les atomes de carbone 16 et 17 du squelette stéroïdique, à condition que R<sub>3</sub> ou R<sub>4</sub> soit absent si ladite liaison entre lesdits atomes de carbone 16 et 17 est présente.

2. Composés selon la revendication 1, caractérisés en ce que R<sub>1</sub> est un groupe aryle contenant comme substituant un groupe acyle ayant 1 à 4 atomes de carbone




où X et Y sont chacun séparément H ou un groupe alkyle saturé ayant 1 à 3 atomes de carbone.

3. Composés selon la revendication 1 ou 2, caractérisés en ce que R<sub>2</sub> est un groupe méthyle ou éthyle.

4. Composés selon les revendications 1 à 3, caractérisés en ce que R<sub>3</sub> représente OH, un groupe alcoxy (C<sub>1</sub>-C<sub>8</sub>), acyle (C<sub>1</sub>-C<sub>6</sub>), alkyle (C<sub>1</sub>-C<sub>6</sub>) comportant facultativement un groupe hydroxyle, ou alcoxyalkyle répondant à la formule C<sub>n</sub>H<sub>2n+1</sub>OC<sub>m</sub>H<sub>2m</sub> où n = 1 à 3 et m = 1 à 3.

5. Composés selon les revendications 1 à 4, caractérisés en ce que R<sub>4</sub> représente H ou un groupe hydrocarbyle (C<sub>1</sub>-C<sub>6</sub>) comportant facultativement un groupe hydroxyle.
- 5      6. Composés selon les revendications 1 à 3, caractérisés en ce que R<sub>3</sub> et R<sub>4</sub> forment ensemble un système hétérocyclique dont le cycle contient 5 atomes.
7. Procédé de préparation des composés selon la revendication 1, caractérisé en ce qu'un composé répondant à la formule :




25 dans laquelle R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> et R<sub>4</sub> ont la même signification que dans la revendication 1, étant entendu que si R<sub>1</sub>, R<sub>3</sub> et/ou R<sub>4</sub> représentent un groupe contenant de l'oxygène, R<sub>1</sub>, R<sub>3</sub> et/ou R<sub>4</sub> peuvent également représenter un groupe contenant de l'oxygène dont l'atome d'oxygène est protégé par un groupe hydrolysable, et dans laquelle R<sub>6</sub> et R<sub>7</sub> représentent chacun un groupe alkyle contenant 1 à 4 atomes de carbone, ou bien R<sub>6</sub> et R<sub>7</sub> représentent ensemble un groupe alkylène contenant 2 à 5 atomes de carbone, est déshydraté et hydrolysé pour former des composés selon la revendication 1, et en ce qu'ensuite, éventuellement, des composés comprenant un groupe OH à la position 17 $\alpha$  ou 17 $\beta$  sont déshydratés, estérifiés ou éthérifiés et, éventuellement, des composés comprenant un radical hydrocarboné comportant un ou plusieurs groupes hydroxyle sont estérifiés, éthérifiés ou oxydés.

30

- 35 8. Composition pharmaceutique comprenant un composé selon la revendication 1 comme ingrédient actif.


35 Revendications pour les Etats contractants suivants : ES, GR

- 40 1. Procédé de préparation de dérivés stéroïdiques arylés à la position 11, ayant la structure suivante :



dans laquelle

R<sub>1</sub> est un groupe aryle homocyclique ou hétérocyclique ayant l'un des substituants suivants : un radical hydrocarboné facultativement saturé ou insaturé, ramifié ou non ramifié, contenant 1 à 10 atomes de carbone, le radical hydrocarboné comportant facultativement un groupe hydroximino, oxo et/ou hydroxyle ; ou un groupe



5

où X et Y sont chacun séparément H ou un radical hydrocarboné ( $C_1-C_4$ ) ou bien forment ensemble un radical hydrocarboné ( $C_2-C_6$ ) ;


$R_2$  est un groupe alkyle contenant 1 à 4 atomes de carbone ;

$R_3$  est H, OH, un radical hydrocarboné saturé ou insaturé contenant 1 à 8 atomes de carbone, comportant facultativement un ou plusieurs groupes hydroxyle, azido, nitrile, oxo et/ou halogéno, ou bien est un groupe acyloxy ( $C_1-C_{18}$ ) ou alcoxyalkyle ( $C_2-C_8$ ) ou acyle ( $C_1-C_{18}$ ) ou alcoxy ( $C_1-C_{12}$ ) ;

$R_4$  est H, OH, un radical hydrocarboné saturé ou insaturé contenant 1 à 8 atomes de carbone, comportant facultativement un ou plusieurs groupes hydroxyle, azido, nitrile, oxo et/ou halogéno, ou bien est un groupe acyloxy ( $C_1-C_{18}$ ) ou alcoxyalkyle ( $C_2-C_8$ ) ou acyle ( $C_1-C_{18}$ ) ou alcoxy ( $C_1-C_{12}$ ) ; ou bien  $R_3$  et  $R_4$  forment ensemble un système cyclique ou un groupe alkylidène ayant 1 à 6 atomes de carbone et le trait en pointillé représente une liaison facultative entre les atomes de carbone 16 et 17 du squelette stéroïdique, à condition que  $R_3$  ou  $R_4$  soit absent si ladite liaison entre lesdits atomes de carbone 16 et 17 est présente,

caractérisé en ce qu'un composé répondant à la formule :

25




35

dans laquelle  $R_1$ ,  $R_2$ ,  $R_3$  et  $R_4$  ont les significations données précédemment, étant entendu que si  $R_1$ ,  $R_3$  et/ou  $R_4$  représentent un groupe contenant de l'oxygène,  $R_1$ ,  $R_3$  et/ou  $R_4$  peuvent également représenter un groupe contenant de l'oxygène dont l'atome d'oxygène est protégé par un groupe hydrolysable, et dans laquelle  $R_6$  et  $R_7$  représentent chacun un groupe alkyle contenant 1 à 4 atomes de carbone, ou bien  $R_6$  et  $R_7$  représentent ensemble un groupe alkylène contenant 2 à 5 atomes de carbone, est déshydraté et hydrolysé pour former les composés désirés et en ce qu'ensuite, éventuellement, des composés comprenant un groupe OH à la position 17α ou 17β sont déshydratés, estérifiés ou éthérifiés et, éventuellement, des composés comprenant un radical hydrocarboné comportant un ou plusieurs groupes hydroxyle sont estérifiés, éthérifiés ou oxydés.

45

2. Procédé de préparation de dérivés stéroïdiques arylés à la position 11 selon la revendication 1, caractérisé en ce que  $R_1$  est un groupe aryle contenant comme substituant un groupe acyle ayant 1 à 4 atomes de carbone ou un groupe

50



55

où X et Y sont chacun séparément H ou un groupe alkyle saturé ayant 1 à 3 atomes de carbone.


3. Procédé de préparation de dérivés stéroïdiques arylés à la position 11 selon la revendication 1 ou 2, caractérisé en ce que  $R_2$  est un groupe méthyle ou éthyle.

4. Procédé de préparation de dérivés stéroïdiques arylés à la position 11 selon les revendications 1 à 3, caractérisé en ce que R<sub>3</sub> représente OH, un groupe alcoxy (C<sub>1</sub>-C<sub>8</sub>), acyle (C<sub>1</sub>-C<sub>6</sub>), alkyle (C<sub>1</sub>-C<sub>6</sub>) comportant facultativement un groupe hydroxyle, ou alkoxyalkyle répondant à la formule C<sub>n</sub>H<sub>2n+1</sub>OC<sub>m</sub>H<sub>2m</sub> où n = 1 à 3 et m = 1 à 3.
5. Procédé de préparation de dérivés stéroïdiques arylés à la position 11 selon les revendications 1 à 4, caractérisé en ce que R<sub>4</sub> représente H ou un groupe hydrocarbyle (C<sub>1</sub>-C<sub>6</sub>) comportant facultativement un groupe hydroxyle.
10. 6. Procédé de préparation de dérivés stéroïdiques arylés à la position 11 selon les revendications 1 à 3, caractérisé en ce que R<sub>3</sub> et R<sub>4</sub> forment ensemble un système hétérocyclique dont le cycle contient 5 atomes.

**Patentansprüche**


15. Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, LI, DE, FR, GB, IT, NL, SE

1. 11-Arylsteroidderivate, dadurch gekennzeichnet, dass diese Derivate die folgende Formel aufweisen :



30. in welcher

R<sub>1</sub> eine homocyclische oder heterocyclische Arylgruppe mit einem der folgenden Substituenten ist: einem gegebenenfalls gesättigten oder ungesättigten, verzweigten oder unverzweigten Kohlenwasserstoffrest mit 1 bis 10 Kohlenstoffatomen, wobei der Kohlenwasserstoffrest gegebenenfalls mit einer Hydroxyimino-, Oxo- und/oder Hydroxylgruppe versehen ist; oder eine Gruppe




45. Gruppe, in welcher X und Y jedes für sich H oder ein (1-4 C)-Kohlenwasserstoffrest ist oder beide zusammen ein (2-6 C)-Kohlenwasserstoffrest bilden;

R<sub>2</sub> eine Alkylgruppe mit 1-4 Kohlenstoffatomen ist;


R<sub>3</sub> H, OH, ein gesättigter oder ungesättigter Kohlenwasserstoffrest mit 1-8 Kohlenstoffatomen, welcher gegebenenfalls mit einem oder mehreren Hydroxyl-, Azido-, Nitril-, Oxo- und/oder Halogengruppen versehen ist, oder eine (1-18 C)-Acyloxy- oder (1-8 C)Alkoxyalkyl- oder eine (1-18 C)-Acyl- oder eine (1-12 C)-Alkoxygruppe ist;

R<sub>4</sub> H, OH, eine gesättigte oder ungesättigte Kohlenwasserstoffgruppe mit 1-8 Kohlenstoffatomen, welche gegebenenfalls mit einem oder mehreren Hydroxyl-, Azido-, Nitril-, Oxo- und/oder Halogengruppen versehen sein kann, oder eine (1-18 C)-Acyloxy- oder (2-8 C)Alkoxyalkyl- oder (1-18 C)-Acyl- oder (1-12 C)-Alkoxygruppe ist; oder R<sub>3</sub> und R<sub>4</sub> zusammen ein Ringsystem oder eine Alkylidengruppe mit 1-6 Kohlenstoffatomen bilden und die gestrichelte Linie eine gegebenenfalls vorhandene Bindung zwischen den Kohlenstoffatomen 16 und 17 des Steroidskelettes sein kann, unter der Voraussetzung, dass R<sub>3</sub> oder R<sub>4</sub> abwesend ist, wenn diese Bindung zwischen den genannten Kohlenstoffatomen 16 und 17 vorhanden ist.

2. Verbindungen nach Anspruch 1, dadurch gekennzeichnet, dass R<sub>1</sub> eine Arylgruppe ist, welche als Substituenten eine Acylgruppe mit 1-4 Kohlenstoffatomen oder eine Gruppe



- 10 ist, in welcher X und Y getrennt H oder eine gesättigte Alkylgruppe mit 1-3 Kohlenstoffatomen ist.
3. Verbindungen nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass R<sub>2</sub> Methyl oder Aethyl ist.
- 15 4. Verbindungen nach den Ansprüchen 1-3, dadurch gekennzeichnet, dass R<sub>3</sub> OH, (1-8 C)-Alkoxy, (1-6 C)-Acyl, (1-6 C)-Alkyl, das gegebenenfalls mit einer Hydroxylgruppe versehen ist, oder Alkoxyalkyl der Formel C<sub>n</sub>H<sub>2n+1</sub>OC<sub>m</sub>H<sub>2m</sub> ist, in welcher n = 1-3 und m = 1-3 bedeutet.
- 20 5. Verbindungen nach den Ansprüchen 1-4, dadurch gekennzeichnet, dass R<sub>4</sub> H oder (1-6 C)-Kohlenwasserstoff ist, welcher gegebenenfalls mit einer Hydroxylgruppe versehen ist.
6. Verbindungen nach den Ansprüchen 1-3, dadurch gekennzeichnet, dass R<sub>3</sub> und R<sub>4</sub> zusammen ein heterocyclisches Ringsystem bilden, welches fünf Atome im Ring enthält.
- 25 7. Verfahren zur Herstellung von Verbindungen nach Anspruch 1, dadurch gekennzeichnet, dass eine Verbindung der Formel :




in welcher R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> und R<sub>4</sub> dieselbe Bedeutung wie in Anspruch 1 aufweisen, unter der Voraussetzung, dass wenn R<sub>1</sub>, R<sub>3</sub> und/oder R<sub>4</sub> eine sauerstoffhaltige Gruppe bedeutet, R<sub>1</sub>, R<sub>3</sub> und/oder R<sub>4</sub> ebenfalls eine sauerstoffhaltige Gruppe sein können, wobei das Sauerstoffatom mit Hilfe einer hydrolysierbaren Gruppe geschützt ist, und in welcher R<sub>6</sub> und R<sub>7</sub> eine Alkylgruppe mit 1-4 Kohlenstoffatomen darstellt oder R<sub>6</sub> und R<sub>7</sub> zusammen eine Alkylengruppe mit 2-5 Kohlenstoffatomen darstellen, dehydratisiert und hydrolysiert wird, um Verbindungen nach Anspruch 1 zu bilden, und dass anschliessend, falls erwünscht, Verbindungen, welche eine OH-Gruppe in Stellung 17α oder 17β enthalten, dehydratisiert, verestert oder veräthert werden und, falls erwünscht, Verbindungen, welche einen Kohlenwasserstoffrest enthalten, der mit einer oder mehreren Hydroxylgruppen versehen ist, verestert, veräthert oder oxidiert werden.

8. Pharmazeutische Zusammensetzung, welche eine Verbindung nach Anspruch 1 als aktiven Bestandteil enthält.

55 Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung von 11-Arylsteroidderivaten, welche die folgende Formel aufweisen:




in welcher

- 15      R<sub>1</sub>    eine homocyclische oder heterocyclische Arylgruppe mit einem der folgenden Substituenten ist: einem gegebenenfalls gesättigten oder ungesättigten, verzweigten oder unverzweigten Kohlenwasserstoffrest mit 1 bis 10 Kohlenstoffatomen, wobei der Kohlenwasserstoffrest gegebenenfalls mit einer Hydroxyiminio-, Oxo- und/oder Hydroxylgruppe versehen ist; oder eine Gruppe



- 25      Gruppe, in welcher X und Y jedes für sich H oder ein (1-4 C)-Kohlenwasserstoffrest ist oder beide zusammen einen (2-6 C)-Kohlenwasserstoffrest bilden;
- R<sub>2</sub>    eine Alkylgruppe mit 1-4 Kohlenstoffatomen ist;
- R<sub>3</sub>    H, OH, ein gesättigter oder ungesättigter Kohlenwasserstoffrest mit 1-8 Kohlenstoffatomen, welcher gegebenenfalls mit einem oder mehreren Hydroxy-, Azido-, Nitril-, Oxo- und/oder Halogengruppen versehen ist, oder eine (1-18 C)-Acyloxy- oder (1-8 C)-Alkoxyalkyl- oder eine (1-18 C)-Acyl- oder eine (1-12 C)-Alkoxygruppe ist;
- R<sub>4</sub>    H, OH, eine gesättigte oder ungesättigte Kohlenwasserstoffgruppe mit 1-8 Kohlenstoffatomen, welche gegebenenfalls mit einem oder mehreren Hydroxyl-, Azido-, Nitril-, Oxo- und/oder Halogengruppen versehen sein kann, oder eine (1-18 C)-Acyloxy- oder (2-8 C)-Alkoxyalkyl- oder (1-18 C)-Acyl- oder (1-12 C)-Alkoxygruppe ist; oder R<sub>3</sub> und R<sub>4</sub> zusammen ein Ringsystem oder eine Alkylidengruppe mit 1-6 Kohlenstoffatomen bilden und die gestrichelte Linie eine gegebenenfalls vorhandene Bindung zwischen den Kohlenstoffatomen 16 und 17 des Steroidskelettes sein kann, unter der Voraussetzung, dass R<sub>3</sub> und R<sub>4</sub> abwesend ist, wenn diese Bindung zwischen den genannten Kohlenstoffatomen 16 und 17 vorhanden ist,
- 40      dadurch gekennzeichnet, dass eine Verbindung der Formel :




- 55      in welcher R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> und R<sub>4</sub> dieselbe Bedeutung wie oben aufweisen, unter der Voraussetzung, dass, wenn R<sub>1</sub>, R<sub>3</sub> und/oder R<sub>4</sub> eine sauerstoffhaltige Gruppe bedeutet, R<sub>1</sub>, R<sub>3</sub> und/oder R<sub>4</sub> ebenfalls eine sauerstoffhaltige Gruppe sein kann, wobei das Sauerstoffatom mit Hilfe einer hydrolysierbaren Gruppe geschützt ist, und in welcher R<sub>6</sub> und R<sub>7</sub> eine Alkylgruppe mit 1-4 Kohlenstoffatomen darstellt oder R<sub>6</sub>

und R<sub>7</sub> zusammen eine Alkylengruppe mit 2-5 Kohlenstoffatomen darstellen, dehydratisiert und hydrolysiert wird, um die gewünschten Verbindungen zu bilden, und dass anschliessend, falls erwünscht, Verbindungen, welche eine OH-Gruppe in Stellung 17 $\alpha$  oder 17 $\beta$  enthalten, dehydratisiert, verestert oder veräthert werden und, falls erwünscht, Verbindungen, die einen Kohlenwasserstoffrest enthalten, der mit einer oder mehreren Hydroxylgruppen versehen ist, verestert, veräthert oder oxidiert werden.

- 5        2. Verfahren zur Herstellung von 11-Arylsteroidderivaten nach Anspruch 1, dadurch gekennzeichnet, dass R<sub>1</sub> eine Arylgruppe ist, welche als Substituenten eine Acylgruppe mit 1-4 Kohlenstoffatomen enthält, oder eine Gruppe

10



15

in welcher X und Y getrennt H oder eine gesättigte Alkylgruppe mit 1-3 Kohlenstoffatomen sind.

- 20        3. Verfahren zur Herstellung von 11-Arylsteroidderivaten nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass R<sub>2</sub> Methyl oder Aethyl ist.
- 25        4. Verfahren zur Herstellung von 11-Arylsteroidderivaten nach den Ansprüchen 1-3, dadurch gekennzeichnet, dass R<sub>3</sub> OH, (1-8 C)-Alkoxy, (1-6 C)-Acyl, (1-6 C)-Alkyl, das gegebenenfalls mit einer Hydroxylgruppe versehen ist, oder Alkoxyalkyl mit der Formel C<sub>n</sub>H<sub>2n+1</sub>OC<sub>m</sub>H<sub>2m</sub>, in welcher n = 1-3 und m = 1-3 ist.
- 30        5. Verfahren zur Herstellung von 11-Arylsteroidderivaten nach den Ansprüchen 1-4, dadurch gekennzeichnet, dass R<sub>4</sub> H oder (1-6 C)-Kohlenwasserstoff, der gegebenenfalls mit einer Hydroxylgruppe versehen ist, bedeutet.
6. Verfahren zur Herstellung von 11-Arylsteroidderivaten nach den Ansprüchen 1-3, dadurch gekennzeichnet, dass R<sub>3</sub> und R<sub>4</sub> zusammen ein heterocyclisches Ringsystem bilden, welches fünf Atome im Ring enthält.

35

40

45

50

55